Literature DB >> 31662862

A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection.

Theodore Rokkas1, Javier P Gisbert2, Antonio Gasbarrini3, Georgina L Hold4, Herbert Tilg5, Peter Malfertheiner6, Francis Megraud7, Colm O'Morain8.   

Abstract

Background: Recurrence remains a challenge in Clostridium difficile infection (CDI), and in this field fecal microbiota transplantation (FMT) has attracted significant interest. Network meta-analysis (NWM) has been established as an evidence-synthesis tool that incorporates direct and indirect evidence in a collection of randomized controlled trials. So far no NWM exists concerning therapeutic interventions for recurrent CDI (rCDI). Objective: In this NWM we assessed the comparative effectiveness of various therapies for rCDI to examine the efficacy rank order and determine the optimum therapeutic approach.
Methods: A Bayesian network meta-analysis was performed to investigate the efficacy rank order of rCDI interventions.
Results: Six eligible RCTs were entered into an NWM. They included 348 rCDI patients, in whom seven therapeutic interventions were used, i.e. donor fecal microbiota transplantation (DFMT), vancomycin, fidaxomicin, vancomycin + DFMT, vancomycin + bowel lavage, autologous FMT and placebo. DFMT showed the highest efficacy in comparison with vancomycin [odds ratio (95% credible interval), 20.02 (7.05-70.03)] and fidaxomicin (22.01 (4.38-109.63)).
Conclusion: This NWM showed that DFMT is the optimum therapeutic approach for rCDI, as it was the most efficacious among various therapeutic interventions, particularly in comparison with commonly used antibiotics such as vancomycin or fidaxomicin. © Author(s) 2019.

Entities:  

Keywords:  Fecal microbiota transplantation; network meta-analysis; recurrent Clostridium difficile infection; treatment

Mesh:

Substances:

Year:  2019        PMID: 31662862      PMCID: PMC6794697          DOI: 10.1177/2050640619854587

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  35 in total

1.  Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.

Authors:  B EISEMAN; W SILEN; G S BASCOM; A J KAUVAR
Journal:  Surgery       Date:  1958-11       Impact factor: 3.982

Review 2.  Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review.

Authors:  Dimitri Drekonja; Jon Reich; Selome Gezahegn; Nancy Greer; Aasma Shaukat; Roderick MacDonald; Indy Rutks; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2015-05-05       Impact factor: 25.391

3.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

4.  A Microsoft-Excel-based tool for running and critically appraising network meta-analyses--an overview and application of NetMetaXL.

Authors:  Stephen Brown; Brian Hutton; Tammy Clifford; Doug Coyle; Daniel Grima; George Wells; Chris Cameron
Journal:  Syst Rev       Date:  2014-09-29

5.  Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Authors:  Christine H Lee; Theodore Steiner; Elaine O Petrof; Marek Smieja; Diane Roscoe; Anouf Nematallah; J Scott Weese; Stephen Collins; Paul Moayyedi; Mark Crowther; Mark J Ropeleski; Padman Jayaratne; David Higgins; Yingfu Li; Neil V Rau; Peter T Kim
Journal:  JAMA       Date:  2016-01-12       Impact factor: 56.272

6.  Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.

Authors:  Erik R Dubberke; Christine H Lee; Robert Orenstein; Sahil Khanna; Gail Hecht; Dale N Gerding
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

7.  The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis.

Authors:  T Rokkas; J P Gisbert; Y Niv; C O'Morain
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

Review 8.  Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.

Authors:  Zain Kassam; Christine H Lee; Yuhong Yuan; Richard H Hunt
Journal:  Am J Gastroenterol       Date:  2013-03-19       Impact factor: 10.864

Review 9.  Burden of Clostridium difficile on the healthcare system.

Authors:  Erik R Dubberke; Margaret A Olsen
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.

Authors:  Colleen R Kelly; Alexander Khoruts; Christopher Staley; Michael J Sadowsky; Mortadha Abd; Mustafa Alani; Brianna Bakow; Patrizia Curran; Joyce McKenney; Allison Tisch; Steven E Reinert; Jason T Machan; Lawrence J Brandt
Journal:  Ann Intern Med       Date:  2016-08-23       Impact factor: 25.391

View more
  11 in total

1.  Stools' donor recruitment, a challenge in pandemic times.

Authors:  Maria Manuela Estevinho
Journal:  United European Gastroenterol J       Date:  2021-10-22       Impact factor: 4.623

2.  Fresh Versus Frozen Stool for Fecal Microbiota Transplantation-Assessment by Multimethod Approach Combining Culturing, Flow Cytometry, and Next-Generation Sequencing.

Authors:  Jaroslaw Bilinski; Mikolaj Dziurzynski; Pawel Grzesiowski; Edyta Podsiadly; Anna Stelmaszczyk-Emmel; Tomasz Dzieciatkowski; Karol Lis; Martyna Tyszka; Krzysztof Ozieranski; Łukasz Dziewit; Grzegorz W Basak
Journal:  Front Microbiol       Date:  2022-07-01       Impact factor: 6.064

3.  Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent Clostridioides difficile infection.

Authors:  Zainab I Abdali; Tracy E Roberts; Pelham Barton; Peter M Hawkey
Journal:  EClinicalMedicine       Date:  2020-06-27

4.  Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Jie Wu; Liang Lv; Chunlian Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-02-28       Impact factor: 5.293

5.  The Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy.

Authors:  Maria Chiara de Stefano; Benedetta Mazzanti; Francesca Vespasiano; Letizia Lombardini; Massimo Cardillo
Journal:  Antibiotics (Basel)       Date:  2022-04-05

Review 6.  Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study.

Authors:  Mancai Wang; Xiaofeng Xie; Songbo Zhao; Wei Han; Youcheng Zhang
Journal:  Front Microbiol       Date:  2022-08-18       Impact factor: 6.064

Review 7.  Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection.

Authors:  Paul Feuerstadt; Olga C Aroniadis; Felicia L Svedlund; Mariana Garcia; Laura Stong; Mena Boules; Sahil Khanna
Journal:  Dig Dis Sci       Date:  2021-07-18       Impact factor: 3.487

Review 8.  Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.

Authors:  Mette Vesterhus; Tom Hemming Karlsen
Journal:  J Gastroenterol       Date:  2020-03-28       Impact factor: 7.527

9.  The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses.

Authors:  Gabrio Bassotti; Andrea Marchegiani; Pierfrancesco Marconi; Katia Fettucciari
Journal:  Microbiologyopen       Date:  2020-07-12       Impact factor: 3.139

10.  Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies.

Authors:  Theodore Rokkas; Konstantinos Ekmektzoglou; Yaron Niv
Journal:  Ann Gastroenterol       Date:  2021-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.